Market Cap | 1.07B | P/E | - | EPS this Y | 15.60% | Ern Qtrly Grth | - |
Income | -283.26M | Forward P/E | -3.75 | EPS next Y | -8.40% | 50D Avg Chg | -9.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 13.00% |
Dividend | N/A | Price/Book | 2.50 | EPS next 5Y | - | 52W High Chg | -36.00% |
Recommedations | 2.00 | Quick Ratio | 3.18 | Shares Outstanding | 221.32M | 52W Low Chg | 87.00% |
Insider Own | 9.06% | ROA | -29.44% | Shares Float | 129M | Beta | 1.61 |
Inst Own | 84.69% | ROE | -72.00% | Shares Shorted/Prior | 26.72M/24.68M | Price | 5.59 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 1,267,908 | Target Price | 12.40 |
Oper. Margin | - | Earnings Date | May 6 | Volume | 771,362 | Change | -2.44% |
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
JMP Securities | Market Outperform | Mar 1, 24 |
HC Wainwright & Co. | Buy | Mar 1, 24 |
HC Wainwright & Co. | Buy | Jan 16, 24 |
JMP Securities | Market Outperform | Oct 12, 23 |
JMP Securities | Market Outperform | Sep 25, 23 |
Citigroup | Buy | Sep 5, 23 |
TD Cowen | Market Perform | Aug 14, 23 |
HC Wainwright & Co. | Neutral | May 2, 23 |
Morgan Stanley | Overweight | Jan 24, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Flagship Ventures Fund V Gener... | 10% Owner 10% Owner | Jun 06 | Sell | 6.27 | 403,758 | 2,531,563 | 1,380,277 | 06/08/23 |
Flagship Ventures Fund V Gener... | 10% Owner 10% Owner | May 24 | Sell | 6.38 | 545,242 | 3,478,644 | 1,425,334 | 05/26/23 |
MacDonald James J. | EVP & General Counse.. EVP & General Counsel | Jun 13 | Option | 1.48 | 66,796 | 98,858 | 497,396 | 06/15/22 |
Yang Patrick Y | Director Director | Mar 21 | Buy | 7.30 | 28,000 | 204,400 | 174,250 | 03/22/22 |
MacDonald James J. | EVP & General Counse.. EVP & General Counsel | Feb 18 | Sell | 6.28 | 333 | 2,091 | 429,417 | 02/23/22 |
Hordo Christian | EVP, Chief Business.. EVP, Chief Business Officer | Sep 10 | Sell | 25.01 | 64,671 | 1,617,422 | 943,932 | 09/10/21 |
Hordo Christian | EVP, Chief Business.. EVP, Chief Business Officer | Sep 10 | Option | 1.48 | 39,205 | 58,023 | 1,008,603 | 09/10/21 |
Hordo Christian | EVP, Chief Business.. EVP, Chief Business Officer | Sep 07 | Sell | 25 | 8,658 | 216,450 | 969,398 | 09/07/21 |
Hordo Christian | EVP, Chief Business.. EVP, Chief Business Officer | Sep 07 | Option | 1.48 | 7,258 | 10,742 | 970,098 | 09/07/21 |